medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2021, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2021; 37 (4)

Immunological study in a patient with Behcet Syndrome: a case report

Alfonso VME, Casado HI, Díaz DG, Marsán SV, Macías AC

Language: Spanish
References: 15
Page: 1-11
PDF size: 369.02 Kb.


ABSTRACT

Introduction: Behcet's syndrome, also known as Behcet's disease is a chronic autoinflammatory process of low frequency and unknown etiology. It’s an all sizes arteries and veins affecting vasculitis that causes an alteration of endothelial function and is expressed clinically by organ damage at various levels. Its pathogenesis involves genetic, microbial and immunological factors. The most common symptoms are oral and genital ulcers, eye inflammation (uveitis, iritis and retinitis), skin lesions and arthritis.
Objective: to evaluate several inmunological markers in a patient with Behcet syndrome.
Case presentation: 39 years old masculine patientwith clinical diagnosis of Behcet disease with negative acute phase reactants and serological authoinmunity markers and lymphocyte populations within referential range, without evidences of lymphocyte activation. The presence of a double B lymphocyte population and familial background, suggest the presence of a self recognitionB lymphocyte population and the probable presence of genetic factors, respectively. There was a good response to steroids treatment.
Conclusions: The study supports the idea that at baseline, not humoral autoimmunity markers, changes in the values of lymphocyte subpopulations, and evidence of lymphocyte activation is detected, but can not exclude the presence of a population of B lymphocytes self-recognition.


REFERENCES

  1. American Behcets Disease Association. Medical Summary of Behcet's Disease. Actualizado en 2014 por Calamia K. [acceso 10/05/2021]; Disponible en: http://www.behcets.com/site/c.8oIJJRPsGcISF/b.9145655/k.993C/Medical_Summary.htm

  2. Alfonso Valdés ME. Síndrome de Behcet. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2016 [acceso 10/05/21];32(3):[aprox.0p.]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/425

  3. Leccese P, Alpsoy E. Behçet's Disease: An Overview of Etiopathogenesis. Front Immunol. 2019;10:1067. DOI: https://doi:10.3389/fimmu.2019.01067

  4. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47. DOI: https://10.1111/jdv.12107

  5. Solis-Cartas U, Poalasín-NarvaezL, Quintero-Chacón G, Muñoz- Balbín M, Lay-WuilliansM, Solis-Cartas E. Características clínico epidemiológicas de la enfermedad de Behçet. Rev Cuba Reumatol [Internet]. 2016 Abr [acceso 10/05/2021];18(1):3-10. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962016000100002&lng=es.

  6. Gül A, Inanç M, Ocal L, Aral O, Koniçe M. Familial aggregation of Behcet's disease in Turkey. Ann Rheum Dis. 2000 Aug;59(8):622-5. DOI: https://10.1136/ard.59.8.622

  7. Molinari N, Koné Paut I, Manna R, Demaille J, Daures JP, Touitou I Identification of an autosomal recessive mode of inheritance in paediatric Behçet's families by segregation analysis. Am J Med Genet A. 2003 Oct 1;122A(2):115-8. DOI: https://10.1002/ajmg.a.20136

  8. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behc¸et's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009 Oct 15;61(10):1287-96. DOI: https://10.1002/art.24642

  9. Giza M, Koftori D, Chen L, Bowness P. Is Behc¸et's disease a 'class 1-opathy'? The role of HLA-B*51 in the pathogenesis of Behcet's disease. Clin Exp Immunol. 2018 Jan;191(1):11-18. DOI: https://10.1111/cei.13049

  10. Lucherinia OM, Lopalcob G, Cantarinia L, Emmic G, Lopalcod A, Veneritob V, Vitalea A, Iannoneb F. Critical regulation of Th17 cell di?erentiation by serum amyloid-A signalling in Behcet's disease. Immunol Lett. 2018 Sep;201:38-44. DOI: https://10.1016/j.imlet.2018.10.013

  11. Sonmez C, Yucel AA, Yesil TH, Kucuk H, Sezgin B, Mercan R, Yucel AE, Demirel GY.Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet'spatients. Clin Rheumatol. 2018 Oct;37(10):2797-804. DOI: https://10.1007/s10067-018-4049-7

  12. Petrushkin H,Hasan S, Stanford MR, Fortune F, Wallace GR. Behçet's Disease: Do Natural Killer Cells Play a Significant Role? Front Immunol. 2015 Mar 24;6:134. DOI: https://10.3389/fimmu.2015.00134

  13. Mohammad-Ebrahim H, Kamali-Sarvestani E, Mahmoudi M, Beigy M, Karami J, Ahmadzadeh N, Shahram F.Association of killer cell immunoglobulin-like receptor (KIR) genes and their HLA ligands with susceptibility to Behçet's? disease. Scand J Rheumatol. 2018 Mar;47(2):155-163. DOI: https://10.1080/03009742.2017.1340510

  14. Castaño-Núñez Á, Montes-Cano MA, García-Lozano JR, Ortego-Centeno N, García-Hernández FJ, Espinosa G, et al. Association of Functional Polymorphisms of KIR3DL1/DS1 With Behçet's Disease. Front Immunol. 2019 Nov;10:2755. DOI: https://10.3389/fimmu.2019.02755

  15. Zarrabi M, Gholijani N, Shenavandeh S, Aflaki E, Amirghofran Z. IL-38 serum levels in patients with Behcet's disease and the relationship with clinical features. Eur Cytokine Netw. 2019 Sep 1;30(3):82-87. DOI: https://10.1684/ecn.2019.0430




2020     |     www.medigraphic.com